Edition:
India

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

1.72USD
23 Feb 2018
Change (% chg)

$0.09 (+5.52%)
Prev Close
$1.63
Open
$1.69
Day's High
$1.75
Day's Low
$1.65
Volume
275,803
Avg. Vol
180,040
52-wk High
$4.23
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Trevena Inc Says FDA Indicated To Co That PDUFA Date For Olinvo NDA Is Nov 2‍​
Saturday, 6 Jan 2018 

Jan 5 (Reuters) - Trevena Inc ::TREVENA INC - ON JAN 5, FDA INDICATED TO THE CO THAT PDUFA REVIEW DATE FOR OLINVO NDA IS NOV 2‍​.TREVENA SAYS FDA ALSO INDICATED IT PLANS TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS NDA​ - SEC FILING.  Full Article

Trevena Announces FDA Acceptance For Review Of New Drug Application For OLINVO(Oliceridine) Injection
Wednesday, 3 Jan 2018 

Jan 2 (Reuters) - Trevena Inc ::TREVENA ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR OLINVO (OLICERIDINE) INJECTION.SAYS EXPECTS THAT PDUFA DATE FOR NDA WILL BE IN Q4 OF 2018.  Full Article

Trevena Inc says Q3 loss per share $0.27
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Trevena Inc -:Trevena reports third quarter 2017 financial results and announces new positive clinical trial data.Q3 loss per share $0.27.Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Trevena Inc - ‍expects to be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months​.  Full Article

Trevena announces submission of NDA to U.S. FDA for Olinvo
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Trevena Inc :Trevena announces submission of new drug application to U.S. FDA for Olinvo (oliceridine injection).Trevena Inc - "‍look forward to working with FDA during review process and to a potential NDA approval of Olinvo in 2018"​.  Full Article

Trevena announces restructuring to focus resources on commercial strategy
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Trevena Inc :Trevena announces restructuring to focus resources on commercial strategy.Trevena Inc - ‍new drug application for olinvo remains on track​.‍New Drug Application for Olinvo remains on track for submission in October​.Trevena Inc - ‍company is reducing its workforce by approximately 30 percent, or 21 full time employees​.Trevena Inc - ‍company continues to expect to report data later this year from ongoing phase 1 study of TRV250​.Trevena Inc - ‍also expects to incur a charge in Q4 of 2017 of approximately $2.0 million related to reduction ​.Trevena inc - ‍company expects to report cash, cash equivalents and marketable securities as of September 30, 2017 of approximately $76.7 million​.Trevena-Intends to complete ongoing Phase 1 trial of TRV250 for acute migraine, will also assess options for further development of asset.Trevena - ‍estimates workforce reduction, other initiatives, will reduce cash expected to be used in activities over next 3 calendar years by about $40 million​.Trevena Inc - ‍company expects cash, cash equivalents and marketable securities will be sufficient to support operations into Q4 of 2018.Trevena INC - ‍intends to complete ongoing Phase 1 trial of TRV250 for acute migraine​.  Full Article

Trevena Q2 loss per share $0.37
Thursday, 4 Aug 2016 

Trevena Inc : Q2 loss per share $0.37 . Q2 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S . Trevena reports second quarter 2016 financial results and provides corporate update Further company coverage: [TRVN.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Trevena says TRV027 did not achieve primary or secondary endpoints in BLAST-AHF Phase 2B trial in acute heart failure
Monday, 16 May 2016 

Trevena Inc : Expects to focus its efforts on its lead Phase 3 oliceridine pain program and its earlier stage programs .Reports TRV027 did not achieve primary or secondary endpoints in BLAST-AHF Phase 2B trial in acute heart failure.  Full Article

BRIEF-Trevena Inc Says FDA Indicated To Co That PDUFA Date For Olinvo NDA Is Nov 2‍​

* TREVENA INC - ON JAN 5, FDA INDICATED TO THE CO THAT PDUFA REVIEW DATE FOR OLINVO NDA IS NOV 2‍​